Intravitreal Administration of Avacincaptad Pegol in a Nonhuman Primate Model of Dry Age‐Related Macular Degeneration [PDF]
Pharmacology Research and PerspectivesEffect of intravitreal administration of sodium iodate on cynomolgus macaque macula over time. Macula cross sections taken with SD‐OCT. ABSTRACT The lack of effective treatments for dry age‐related macular degeneration (AMD) is in part due to a lack of a preclinical animal model that recapitulates features of the clinical state including macular ...
Aldric Hama
exaly +3 more sources
Real-World Outcomes with Complement Inhibitors for Geographic Atrophy: A Comparative Study of Pegacetacoplan versus Avacincaptad Pegol [PDF]
Clinical OphthalmologyRyan B Rush,1– 3 Westin Klein,1 Robert M Reinauer4 1Department of Ophthalmology, Panhandle Eye Group, Amarillo, TX, USA; 2Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USA; 3Department of Ophthalmology, Southwest ...
Rush RB, Klein W, Reinauer RM
doaj +2 more sources
Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a study [PDF]
BMJ Open OphthalmologyObjective To assess the safety and tolerability of avacincaptad pegol (ACP), a Food and Drug Administration-approved therapy for geographic atrophy, administered in combination with ranibizumab, an approved therapy for neovascular age-related macular ...
David S Boyer +6 more
doaj +2 more sources
Can intravitreal injections with higher volume cause higher intraocular eye pressure? Considerations for anti-complement injections in normal and glaucomatous eyes [PDF]
International Journal of Retina and Vitreous, 2023 The approval of Syfovre® (pegcetacoplan) and Iverzay® (avacincaptad pegol) for the treatment of geographic atrophy (GA) marks a significant advancement in retinal disease therapy, offering both complement 3 and complement 5 inhibitors.
Carsten H. Meyer +2 more
doaj +2 more sources
Clinical Outcomes of Treatment of Geographic Atrophy: A Narrative Review [PDF]
Ophthalmology and TherapyRationale In 2023, the U.S. Food and Drug Administration approved pegcetacoplan (SYFOVRE) as the first therapeutic option for geographic atrophy (GA), a previously untreatable condition associated with age-related macular degeneration.
Anne Helene Køllund Nissen +2 more
doaj +2 more sources
One-Year Outcomes in Subjects Developing Macular Neovascularization While Undergoing Avacincaptad Pegol Therapy for Geographic Atrophy [PDF]
Clinical OphthalmologyRyan B Rush,1– 3 Westin Klein,1 Sloan W Rush,1,2 Robert Reinauer4 1Department of Ophthalmology, Panhandle Eye Group, Amarillo, TX, USA; 2Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USA; 3Department of Ophthalmology ...
Rush RB, Klein W, Rush SW, Reinauer R
doaj +2 more sources
Efficacy and safety of complement inhibitors in patients with geographic atrophy associated with age-related macular degeneration: a network meta-analysis of randomized controlled trials [PDF]
Frontiers in PharmacologyImportanceClinical trials in recent years have shown significant effectiveness of complement inhibitors for geographic atrophy (GA) treatment. Two complement inhibitor drugs have been approved by the Food and Drug Administration (FDA).Objectiveto compare
Huan Wang +9 more
doaj +2 more sources
Off-label intravitreal eculizumab for geographic atrophy: report of the first two cases [PDF]
International Journal of Retina and VitreousPurpose To report the feasibility and short-term safety of off-label intravitreal eculizumab as a complement-inhibition strategy for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), based on two clinical cases.
Rodrigo Jorge +3 more
doaj +2 more sources
Optimizing Oligonucleotide Therapeutics: A Model-Informed Drug Development Perspective. [PDF]
Clin Transl SciABSTRACT Oligonucleotide therapies have emerged as a powerful therapeutic class, providing novel solutions for diverse diseases through antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers that specifically target and modulate gene expression or protein function. However, oligonucleotide development faces distinct challenges,
Yuan Y +7 more
europepmc +2 more sources
Shifting From Systemic to Precision-Targeted Complement Therapies: Opportunities and Hurdles. [PDF]
Eur J ImmunolComplement therapeutics have expanded considerably, but systemic inhibitors remain limited by infection risks, breakthrough events, and loss of physiological functions. Emerging targeted approaches aim for organ‐, tissue‐, or cell‐specific modulation of complement activity, potentially offering greater precision while reducing treatment burden and ...
Mannes M, Zelek WM, Trouw LA.
europepmc +2 more sources